These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 33598731)
1. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials. Fang L; Shi L; Wang W; Hu T; Rao X Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731 [TBL] [Abstract][Full Text] [Related]
2. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Chen YP; Wang ZX; Chen L; Liu X; Tang LL; Mao YP; Li WF; Lin AH; Sun Y; Ma J Ann Oncol; 2015 Jan; 26(1):205-211. PubMed ID: 25355717 [TBL] [Abstract][Full Text] [Related]
3. Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma - An updated meta-analysis and systematic review. Hu T; Fang L; Shi L; Wang W; Huang Y Am J Otolaryngol; 2021; 42(5):102973. PubMed ID: 33812206 [TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis. Bongiovanni A; Vagheggini A; Fausti V; Mercatali L; Calpona S; Di Menna G; Miserocchi G; Ibrahim T Crit Rev Oncol Hematol; 2021 Apr; 160():103244. PubMed ID: 33582249 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410 [TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score-matching studies. Li M; Zhang B; Chen Q; Zhang L; Mo X; Chen Z; Jin Z; Chen L; You J; Zhang S Head Neck; 2021 Jun; 43(6):1912-1927. PubMed ID: 33644916 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis. Zhong Q; Luo D; Li X; Du Q; Liang Q; Liu W; Li J; Zhu X Cancer Biol Ther; 2023 Dec; 24(1):2274121. PubMed ID: 37965924 [TBL] [Abstract][Full Text] [Related]
8. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study. Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950 [TBL] [Abstract][Full Text] [Related]
9. The Changing Role of Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Updated Systemic Review and Network Meta-Analysis. Liu M; You W; Song YB; Miao JD; Zhong XB; Cai DK; Xu L; Xie LF; Gao Y Front Oncol; 2018; 8():597. PubMed ID: 30619740 [No Abstract] [Full Text] [Related]
10. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966 [TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Wei Z; Zhang Z; Luo J; Li N; Peng X J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162 [TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma. Li T; Yang F; Ma K; Lv L Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3333-3344. PubMed ID: 33517538 [TBL] [Abstract][Full Text] [Related]
13. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Chen YP; Tang LL; Yang Q; Poh SS; Hui EP; Chan ATC; Ong WS; Tan T; Wee J; Li WF; Chen L; Ma BBY; Tong M; Tan SH; Cheah SL; Fong KW; Sommat K; Soong YL; Guo Y; Lin AH; Sun Y; Hong MH; Cao SM; Chen MY; Ma J Clin Cancer Res; 2018 Apr; 24(8):1824-1833. PubMed ID: 29431618 [No Abstract] [Full Text] [Related]
14. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis. Tang M; Jia Z; Zhang J Eur Arch Otorhinolaryngol; 2021 May; 278(5):1545-1558. PubMed ID: 32700235 [TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis. Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182 [TBL] [Abstract][Full Text] [Related]
16. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma. Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers. Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689 [TBL] [Abstract][Full Text] [Related]
18. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study. Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907 [TBL] [Abstract][Full Text] [Related]
19. A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone. Zhang ZJ; Shi LL; Hong XH; Xiao BY; Lin GH; Liu Q; Wang BC PLoS One; 2022; 17(3):e0265551. PubMed ID: 35303014 [TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]